Skip to main content
Caplight Logo









SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals

Private
Rockville, MarylandHealthcare & Life Scienceshttps://scineuro.com/

Last Round

VC Round

Dec 4, 2025

Total Funding Raised

$153M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

SciNeuro Pharmaceuticals is a biotechnology company that develops innovative drugs and therapies for the treatment of central nervous system and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyCNS therapeuticsneurodegenerative diseasedrug discoveryclinical-stage biotechsmall molecule therapyantibody therapeuticsLRRK2 inhibitordrug licensingbiotech pipelinecentral nervous systemCNSbiotech startuppharma partnershipdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SciNeuro Pharmaceuticals Comparables

Compare SciNeuro Pharmaceuticals with similar companies based on industry and business-model similarity.

SciNeuro Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neuron23
83%
Korsana Biosciences
82%
Alector
76%

SciNeuro Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 4, 2025
Series BDec 4, 2025
Series ADec 8, 2020

Key People

Founding team and executive leadership

Hogan Wan

Chief Financial Officer

Executive Team

SciNeuro Pharmaceuticals Investors

Notable investors and investment history

SciNeuro Pharmaceuticals investors
InvestorRounds
Boyu CapitalSeries A
Zoo CapitalSeries A
TF CapitalSeries A
ARCH Venture PartnersVC Round, Series B, Series A
ARCH Venture PartnersSeries B, Series A
Sequoia CapitalSeries A
The Michael J. Fox Foundation for Parkinson's ResearchVC Round, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    Developing a new de novo amyloid beta antibody program in collaboration with Novartis.

  • Jan 12, 2026

    Exclusive worldwide licensing deal with Novartis Pharma AG for Alzheimer's drug.

SciNeuro Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SciNeuro Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SciNeuro Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range33
Year Founded2020
Last FundingDec 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.